Literature DB >> 26985120

Risperidone-induced skin rash.

Priya Janardhana1, Anil Kumar Mysore Nagaraj2, P L Basavanna1.   

Abstract

Entities:  

Year:  2016        PMID: 26985120      PMCID: PMC4776573          DOI: 10.4103/0019-5545.174407

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


× No keyword cloud information.
Sir, Antipsychotic agents are known to cause adverse cutaneous reactions in approximately 5% of the individuals of which exanthematous eruptions, skin pigmentation changes, photosensitivity, urticarial, and pruritus are common.[1] Risperidone, a benzisoxazole derivative is an atypical antipsychotic. It exhibits high-affinity antagonism at 5 HT2 and D2 receptors. It binds to alpha1, alpha2 adrenergic receptors to a lesser extent. It has no affinity to cholinergic receptors.[2] It is known to cause various adverse effects out of which cutaneous reaction is very rare. A thorough literature search revealed a few articles of risperidone-induced urticaria, angioneurotic edema, and photosensitivity reactions. We herein present a case of rare adverse effect, risperidone-induced eczematous skin rash. Mr. R, a 20-year-old male presented with complaints of aggressive behavior, self-injurious behavior, delusions of persecution, and third person auditory hallucinations of 2 weeks duration. He had a 3 years history of paranoid schizophrenia, diagnosed as per International Classification of Diseases 10, and was on irregular treatment. The current exacerbation happened after about 6 months of partial remission. Detailed history revealed no previous drug or food allergies. The patient was not on any concomitant drug therapy when he reported though he had taken olanzapine intermittently in the past. The patient was started on oral risperidone 6 mg/day in divided doses and was instructed follow-up after 1 week, as the caretakers were not ready to admit him. When he reported back, he showed clinical improvement but complained of generalized pruritus. Examination revealed excoriation of skin. Dermatologist opinion was taken, and he was treated with terbinafine and chlorpheniramine after total and differential white blood cell count and absolute eosinophil count, which were within normal limits. Simultaneously, the dose of oral risperidone was reduced to 4 mg/day suspecting a drug-induced rash. The patient came back in a week with no improvement in the dermatological complaints but significant reduction in psychotic symptoms. Examination revealed scaling and excoriation of skin. The patient continued to use terbinafine, and the dose of risperidone was reduced to 2 mg/day. In a span of 1 week, the patient reported again with exacerbation of the dermatological symptoms and now showed generalized scaling of the skin, papules, and ulcers with serous discharge over the dorsum of the hand. Risperidone was stopped completely and the dermatologist prescribed hydrocortisone acetate ointment. Follow-up after 1 week, showed considerable recovery of the scaly lesions and it completely disappeared after 2 weeks of discontinuation of risperidone. Even hydrocortisone was stopped after 2 weeks, and there were no fresh skin lesions during subsequent follow-up. Considering the ethical issues involved, re-challenge was not done and an alternative drug olanzapine 10 mg/day was prescribed, to which the patient is compliant and symptomatically better. Figure 1 shows the excoriation while on risperidone and Figure 2 shows the completely healed rash after stopping it.
Figure 1

Skin excoriation while on risperidone

Figure 2

Completely healed rash after stopping risperidone

Skin excoriation while on risperidone Completely healed rash after stopping risperidone On evaluation with the Naranjo causality assessment scale, we obtained a score of 6, which is probable that the adverse reaction was caused by the drug. The adverse reaction, in this case, can be attributed to the immunological or nonimmunological cause. The metabolite of the drug or the excepients used may behave as a hapten and induce a hypersensitivity reaction in immunological etiology whereas the nonimmunological causes can be attributed to drug interactions and metabolic alterations.[3] A broad literature search on PubMed throws light on one article of low dose oral risperidone solution induced cutaneous syndrome reported from Korea in which only the face was involved, and the reaction was acute.[4] In another meta-analysis, risperidone-induced adverse effects was reported in 13,710 subjects, of which only 19 had eczema. Thus, the incidence of cutaneous reactions is <0.1%.[5] The other Indian report is of a case of “giant urticaria” over face and neck with risperidone. Urticaria is an erythematous patch over the skin with elevated ridges (hives).[6] The eczematous rash we are reporting started as pruritus, progressing to desquamation of skin followed by ooze and healing; that had spared head and neck, but involved all other areas. Hence, we are reporting a rare case of risperidone-induced skin rash, the first of its kind being reported in India.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  4 in total

1.  Risperidone-induced recurrent giant urticaria.

Authors:  Biswaranjan Mishra; Sahoo Saddichha; Rakesh Kumar; Sayeed Akhtar
Journal:  Br J Clin Pharmacol       Date:  2007-10       Impact factor: 4.335

2.  Rash and desquamation associated with risperidone oral solution.

Authors:  Beang-Jin Chae; Byung-Jo Kang
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 3.  Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.

Authors:  Dhiren Singh; Daniel W O'Connor
Journal:  Clin Interv Aging       Date:  2009-09-01       Impact factor: 4.458

Review 4.  Adverse cutaneous reactions to antipsychotics.

Authors:  Julia K Warnock; David W Morris
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

  4 in total
  1 in total

1.  Risperidone-induced Erythema Multiforme Minor.

Authors:  Shreyas Shrikant Pendharkar; Shilpa Avinash Telgote; Amol Jadhav; Sachin Bhojne
Journal:  Indian J Psychol Med       Date:  2017 Nov-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.